Bayer reported Phase 3 data showing its oral Factor XIa inhibitor asundexian reduced recurrence of secondary stroke by 26% versus control without raising bleeding rates. The trial readout positions asundexian as a potential safer anticoagulant for secondary prevention following ischemic stroke. Asundexian’s profile—once‑daily oral dosing and a reduced bleeding signal—compares directly with emerging Factor XIa programs from other large developers. The company presented the results publicly and emphasized the drug’s tolerability alongside efficacy. If regulators endorse the balance of efficacy and safety, asundexian could join a new class of antithrombotics that aim to decouple antithrombotic effect from bleeding risk, altering standard of care for stroke prevention.